My primary interest is identification of genetic determinants of drug response through modern methods aimed at addressing pharmacogenomics research and translating that information into new diagnostics and treatment strategies at point-of-care.
My clinical practice and research focus on the drug treatment of epilepsy and the genetic, behavioral, and environmental factors that influence drug response.
